Webinars

Our informative webinars are in partnership with the Journal of Parkinson’s Disease and Parkinson’s Movement.

These quarterly webinars are each chaired by Professor Patrick Brundin (Van Andel Research Institute) who is joined by a different panel of experts discussing important topics and related research within the Parkinson's community.

Re-watch the webinars here...

Webinar - Dyskinesia in Parkinson's

Watch our most recent webinar - 'Dyskinesia in Parkinson's' Read more

Webinar - How Does Parkinson’s Disease Begin? Neuroanatomical Pathways, Prions and Histology.

The panel discuss the paper 'How Does Parkinson’s Disease Begin? Perspectives on Neuroanatomical Pathways, Prions, and Histology' by Professor Per Borghammer Read more

Webinar - Does Exenatide reduce Non-motor Symptoms in Parkinson’s?

Professor Brundin is joined by Professor Tom Foltynie who led the exenatide trial... Read more

Webinar - Sleep and Parkinson’s Disease

Professor Patrik Brundin is joined by a panel of experts discussing ‘Sleep and Parkinson’s Disease’. Read more

Webinar - Targeting the Genetics of Parkinson's

Professor Patrik Brundin leads a panel discussing the genetics of Parkinson's... Read more

Webinar - Stem Cell (Cell Replacement) Therapy

This webinar focuses on developments in the field of stem cell therapy for Parkinson's... Read more

Latest

MIRO - A New Biomarker for Parkinson's?

Researchers at Stanford University in the US looking for new biomarkers of Parkinson's, recently identified a protein called MIRO that in initial data very accurately identifies people with the condition...

The Simvastatin Study Protocol

The Cure Parkinson's Trust (CPT) is co-funding the ongoing PD-STAT clinical trial evaluating the disease modifying potential of the cholesterol lowering drug simvastatin in our Linked Clinical Trials programme. The trial protocol has recently been published...

The Bydureon Phase lll Trial to Begin Recruiting

The next phase of the Exenatide-PD clinical trial will begin recruiting to determine, in a larger cohort, whether this diabetes treatment can slow down disease progression in Parkinson’s...

The Grouse & Grape Luncheon 2019

The ninth annual Grouse & Grape Luncheon was held on Tuesday 8 October at the historic Spencer House, and attracted 300 guests who raised over £35,000 for The Cure Parkinson’s Trust.

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.

New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.

Science news

Read the latest Parkinson's science and research news here.

Trials - Repurposed Drugs

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.

Apply for Funding

The NAC Trial - the facts

Our story

Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

Alpha-synuclein and Parkinson's

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more